ArticleEndocrine pathology2023
High Grade Differentiated Follicular Cell-Derived Thyroid Carcinoma Versus Poorly Differentiated Thyroid Carcinoma: A Clinicopathologic Analysis of 41 Cases.
Article in Endocrine pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Aggressive Thyroid Carcinomas Clinical and Molecular Features: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Current evidences in poorly differentiated thyroid carcinoma: a systematic review and subsection meta-analysis for clinical decision making.Endocrine · 2024Pooled it
- Re-Analyzing Differentiated High-Grade Thyroid Carcinoma and Elevated Ki-67 Proliferation: A Single-Center Retrospective Study.Journal of clinical medicine · 2026Article
- Clinicopathologic and Molecular Features of Poorly Differentiated Thyroid Carcinomas in Adults ≤ 45 Years of Age.Endocrine pathology · 2026Article
- Clinicopathological profile of high-grade differentiated thyroid carcinoma in an Indonesian tertiary hospital.Journal of pathology and translational medicine · 2026Article
- Differentiated high-grade thyroid carcinoma (DHGTC): clinicopathological analysis of a new entity in a chilean center.Endocrine · 2026Observational
- Synchronous metastatic differentiated high-grade thyroid carcinoma in lymph node from classic papillary thyroid carcinoma: a case report and literature review.Frontiers in oncology · 2026Article
- Encapsulated neoplasms of the thyroid gland.Virchows Archiv : an international journal of pathology · 2026Review
- Diagnostic Challenges, Prognostic Assessment, and Treatment Strategies in High-Grade Differentiated Thyroid Carcinoma.Endocrinology and metabolism (Seoul, Korea) · 2025Review
- Thyroid cancer: From molecular insights to therapy (Review).Oncology letters · 2025Review
- Spatial Transcriptomics Reveals Transcriptomic and Immune Microenvironment Reprogramming during Thyroid Carcinoma Dedifferentiation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- High Prevalence of Potential Molecular Therapeutic Targets in Poorly Differentiated Thyroid Carcinoma.Endocrine pathology · 2025Article
- Comparative analysis of follicular cell- derived thyroid carcinoma: assessing the impact of high-grade features in an advanced disease cohort.Virchows Archiv : an international journal of pathology · 2025Article
- Clinicopathologic and Molecular Analysis of 15 Pediatric and Young Adult Patients with High-Grade Non-anaplastic Thyroid Carcinoma.Endocrine pathology · 2024Article
- Aggressive Types of Malignant Thyroid Neoplasms.Journal of clinical medicine · 2024Review
- RAS-Mutant Follicular Thyroid Tumors: A Continuous Challenge for Pathologists.Endocrine pathology · 2024Review
- Ki-67 Labelling Index as a Predictor of Invasive Features in Thyroid Cancer: Retrospective Analysis and Implications.Current oncology (Toronto, Ont.) · 2024Article
- The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review.Journal of personalized medicine · 2024Review
- A Comprehensive Review and Insights into the New Entity of Differentiated High-Grade Thyroid Carcinoma.Current oncology (Toronto, Ont.) · 2024Review
- Clinical and Paraclinical Considerations Regarding ki67's Role in the Management of Differentiated Thyroid Carcinoma-A Literature Review.Medicina (Kaunas, Lithuania) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Criteria overlap for separating between malignant follicular epithelial cell-derived thyroid gland neoplasms with high grade features of increased mitoses and tumor necrosis but lacking anaplastic histology. Patterns of growth, nuclear features, tumor necrosis, and various mitotic index cutoffs are suggested, but a reproducible Ki-67-based labeling index has not been established. Forty-one cases diagnosed as poorly differentiated thyroid carcinoma (PDTC) or high grade differentiated follicular cell-derived thyroid carcinoma (HGDFCDTC) were reviewed, with histologic features, mitotic figure counts, and Ki-67 labeling index reviewed on cases within Southern California Permanente Medical Group from 2010 to 2021 to establish any potential outcome differences. There were 17 HGDFCDTC (nine papillary thyroid carcinoma; eight oncocytic follicular thyroid carcinoma), median age 64 years, affecting nine females and eight males. Tumors were large (median, 6.0 cm), usually unifocal (n = 13), with only one tumor lacking invasion. Tumor necrosis was present in all; median mitotic count was 5/2 mm
Indexed as
Identifiers
37195480What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.